Answers are grounded in this paper and cite their sources.
Urolithiasis is a recurrent renal disease characterized by calcium oxalate crystal deposition, oxidative stress, and gradual deterioration of renal function. Although several pharmacological options exist, high recurrence rates necessitate more effective multi-target therapeutic approaches. Aim. To evaluate the antiurolithiatic and nephroprotective effects of tamsulosin (TAM) alone and in combination with β-carotene (TAM + BC) in an ethylene glycol (EG)- induced urolithiasis model in rats. Materials and methods. An in vitro calcium oxalate crystallization assay was conducted to evaluate the calcium oxalate crystal inhibition potential of TAM and TAM + BC. Male Wistar rats were subjected to experimental urolithiasis for 21 days using an EG and ammonium chloride regimen. Animals were assigned to seven experimental groups: control, disease control, standard (Cystone 750 mg/kg), TAM-treated (1 mg/kg and 3 mg/kg), and two TAM+BC combination groups. Antiurolithiatic efficacy was evaluated via serum biomarkers, urinary electrolytes, tissue oxidative stress parameters, crystal counts, and histopathology. Results. Disease control animals exhibited severe renal dysfunction, oxidative stress, electrolyte imbalance, and tubular crystal retention (p < 0.001). Treatment with TAM alone and TAM + BC significantly decreased serum urea, creatinine, blood urea nitrogen, and uric acid (p < 0.05-0.001). Urinary oxalate, uric acid, calcium, and sodium excretion were markedly reduced, whereas citrate, magnesium, and potassium levels were significantly increased. Antioxidant enzyme activities were restored, and lipid peroxidation was reduced. Histopathological evaluation confirmed a substantial reduction in crystal deposits and tissue injury, with maximum nephroprotection observed in the combination therapy groups. Conclusions. Both TAM alone and the TAM + BC combination provide marked antiurolithiatic and nephroprotective activity through modulation of oxidative stress, alleviation of urinary risk factors, and restoration of renal biochemical balance. Combination therapy represents a promising strategy for urolithiasis management.
No takes yet. Share an insight, caveat, or question.
Muzammil et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: